PTGS2 and metabolic dysfunction-associated steatotic liver disease: Although it has previously been demonstrated that celecoxib, a COX‐2 selective non‐steroidal anti‐inflammatory drug (NSAID) widely prescribed for relieving arthritis‐related pain, alleviates high‐fat diet (HFD)‐induced hepatic steatosis10 and metabolic steatohepatitis in murine models,9, 11 the precise mechanisms by which suppression of de novo lipogenesis contributes to its role in the lipogenic NAFLD phenotype need to be better defined.